inno.N

Integrated R&D Hub 'HK inno.N Square' opened

'K-CAB tab.' finished exports to the Australia and New Zealand (accumulated overseas 47 countries)

Approval of product licensing for 'K-CAB tab.' in Malaysia
Approval of product licensing for 'K-CAB tab.' in Latin America(Dominican Republic, Nicaragua, Honduras, Guatemala, El Salvador, Colombia)

Receives certification for 'ISO 50001', international standards for energy management systems
Agreement signed for 'Omapone' to export to Uzbekistan
Agreement signed for 'Exone-R' to export to Chile

Published a '2023 Sustainability Report'

Receives certification for 'ISO 27001', international standards for information security management systems
Acquires a next-generation GLP-1 analog for anti-obesity treatment

'K-CAB tab.' finished exports to the Middle East and North Africa
'K-CAB' won the IR52 Jang Young-sil Award (1st prize, the Prime Minister Award)
Agreement signed for 'Machkhan' to export to Vietnam

Received the award of outstanding corporation (outstanding corporation in IR activities) in KOSDAQ market disclosure
Published a white paper on social contribution

'K-CAB' selects excellent technology in the field of life science for "2023 Industrial Technology Performance" (National Academy of Engineering of Korea)

Agreement signed for 'Citopcin', 'Levotopcin', and 'Cinezolid' to export to Panama

Approval of product licensing for 'Omapone' and 'Omapone Plus'

Published a '2022 Sustainability Report'

Approval of product licensing for 'K-CAB tab.' in Peru

Establishment of the Sustainable Management Committee

Approval of product licensing for 'K-CAB tab.' in Mexico
Published a white paper on social contribution

Approval of product licensing for 'K-CAB tab.' in Singapore

Technologies for the manufacturing of 'K-CAB tab.' are exported to Brazil
'K-CAB.' achieved 132.1billion won in prescription sales in 2022 (UBIST DATA standards)
Receives certification for 'ISO 37301' and 'ISO 37001', international standards for compliance management system and corruption prevention

Published a '2021 Sustainability Report'
Receives certification for 'ISO 14001', Environmental management systems

Approval of product licensing for 'K-CAB tab.' in Indonesia
'K-CAB tab.' enters phase 3 clinical trials in USA

Selected as an excellent company for gender equality awarded by the Minister of Employment and Labor
Approval of product licensing for 'K-CAB tab.' in Philippines
Agreement is signed for 'K-CAB tab.' to be exported to 7 countries including India

'K-CAB tab.' launches in China

'K-CAB tab.' achieved 110.7billion won in prescription sales in 2021 (UBIST DATA standards)
Agreement is signed for 'K-CAB tab.' to be exported to the Malaysia
Technologies for the manufacturing of 'K-CAB tab.' are exported to USA and Canada
Received the 'KODAQ Award' (Best Job Creation Company Award, hosted by KOSDAQ Association)
Agreement signed for 'Cinezolid' and 'Ompaone' to export to Philippines

Approval of product licensing for 'K-CAB tab.' in Mongolia

Agreement signed for 'Omapone' to export to Kazakhstan

Listed on KOSDAQ

Selected among the top 100 Asian companies that are best to work for (hosted by GWP Korea)

Technologies for 'K-CAB' in injection form are exported to China
Agreement signed for 'Exone' to export to Vietnam

Agreement is signed for 'K-CAB tab.' to be exported to the Vietnam

Selected among the top 100 companies that are best to work for (hosted by GWP Korea)

The Ministry of Industry’s Prize is given at the 22nd Korea Brand Awards (for 'CONDITION')
The Prime Minister’s Prize is given at the Korea New Growth Management Awards
Agreement signed for 'Epokine' to export to Philippines

Agreement is signed for 'K-CAB tab.' to be exported to the Singapore

Agreement is signed for 'K-CAB tab.' to be exported to the Mongolia
Construction of the Osong Plant for IV fluids is completed and approved for operations

Company name is changed from CJ Healthcare Co. Ltd. to HK inno.N Corporation

Agreement signed for 'Exone', 'Exone-R', and 'Machkhan' to export to Philippines

Agreement is signed for 'K-CAB tab.' to be exported to the Philippines

Agreement is signed for 'K-CAB tab.' to be exported to Thailand
Receives certification for 'ISO 37001', an international standard for corruption prevention

Agreement is signed for 'K-CAB tab.' to be exported to Indonesia

'K-CAB tab.' is launched in Korea

Grand Prize for novel drug development is awarded at the 20th Korea Novel Drug Development Awards

Agreement is signed for 'K-CAB tab.' to be exported to 17 countries in Latin America

Awarded as an innovative pharmaceutical firm (Minister of Health and Welfare’s Prize; Prize from the President of the Korea Healthcare Industry Promotion Institute)

Approval received from Korean authorities for the use of 'K-CAB tab.' for GERD (30th novel drug to be registered in Korea)

Incorporated as subsidiary of Kolmar Korea Co. Ltd.

Technologies for the manufacturing of 2nd generation EPO (drug to treat anemia) are exported to China
Acquired grade ‘AA’ in the evaluation by the Fair Trade Commission for autonomous compliance

Technologies for the manufacturing of 2nd generation EPO (drug to treat anemia) are exported to Japan

Day of autonomous compliance is designated (April 1)

The Technology Export Prize is awarded at the 17th Korea Novel Drug Development Award (for 'K-CAB')

Technologies for the manufacturing of 'K-CAB tab.' to treat GERD (with Tegoprazan as the active ingredient) are exported to China

Separated into CJ Healthcare Co. Ltd.

Selected as an 'innovative pharmaceutical firm' certified by the Ministry of Health and Welfare

The Osong Plant receives the 'Beautiful Architecture' Prize by Cheongwon-Gun Office

'CONDITION' is selected as a 'world-class product' by the Ministry of Industry

The construction of the Osong Plant for manufacturing finished pharmaceutical products of global is completed

Groundbreaking for the Osong Plant (150 billion won is invested)

Acquires Hanil Pharmaceutical

'Pseudovaccin', a vaccine for Pseudomonas aeruginosa, is registered as Korea's 7th novel drug

Korea's first sales organization dedicated to anti-cancer drugs is launched

'Epokine', a new drug to treat anemia, is launched (the first of its kind in Korea and the third to be launched worldwide)

Injection 'Citopcin' receives the Chang Yeongsil Prize

'CONDITION' is launched

New plant for IV fluids is completed

'7-ACA', an active pharmaceutical ingredient for antibiotics, is launched
Daeso Plant is completed

The Icheon Plant completes its construction

'Hepaxin-B', a vaccine for Hepatitis B is developed using domestic technologies only and launched in the market

The establishment of a comprehensive research institute marks the company's foray into the pharmaceuticals business